A U.S. Patent for a “Cell Culture Process” was awarded to Momenta Pharma on March 10th, 2020. The present invention is a method of manufacturing a preparation of adalimumab, comprising: culturing a cell in a medium comprising 1.5 g/L arginine to 20 g/L arginine under conditions in which the cell expresses adalimumab; isolating the adalimumab, thereby producing a preparation of adalimumab; and formulating the preparation into a drug product if the preparation meets a target value of one or more C-terminal variants of adalimumab, wherein the C-terminal variants differ in amino acid sequence only by the presence or absence of a lysine… Learn More